SeaCrest Wealth Management LLC lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.5% in the second quarter, HoldingsChannel.com reports. The firm owned 101,271 shares of the biopharmaceutical company’s stock after selling 1,552 shares during the period. Pfizer comprises about 0.7% of SeaCrest Wealth Management LLC’s investment portfolio, making the stock its 22nd biggest position. SeaCrest Wealth Management LLC’s holdings in Pfizer were worth $3,674,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. HC Financial Advisors Inc. acquired a new stake in Pfizer during the 4th quarter worth approximately $2,685,000. Inverness Counsel LLC NY lifted its position in Pfizer by 11.0% during the 1st quarter. Inverness Counsel LLC NY now owns 44,765 shares of the biopharmaceutical company’s stock worth $1,589,000 after acquiring an additional 4,432 shares during the period. Dean Capital Investments Management LLC lifted its position in Pfizer by 37.3% during the 1st quarter. Dean Capital Investments Management LLC now owns 84,293 shares of the biopharmaceutical company’s stock worth $2,992,000 after acquiring an additional 22,891 shares during the period. West Branch Capital LLC acquired a new stake in Pfizer during the 1st quarter worth approximately $1,388,000. Finally, Mirador Capital Partners LP lifted its position in Pfizer by 3.6% during the 1st quarter. Mirador Capital Partners LP now owns 48,953 shares of the biopharmaceutical company’s stock worth $1,792,000 after acquiring an additional 1,706 shares during the period. Hedge funds and other institutional investors own 68.95% of the company’s stock.

In related news, VP Loretta V. Cangialosi sold 26,814 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The stock was sold at an average price of $40.16, for a total value of $1,076,850.24. Following the completion of the transaction, the vice president now directly owns 102,360 shares of the company’s stock, valued at approximately $4,110,777.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kirsten Lund-Jurgensen sold 20,942 shares of the firm’s stock in a transaction that occurred on Wednesday, August 1st. The shares were sold at an average price of $40.04, for a total value of $838,517.68. Following the completion of the transaction, the executive vice president now directly owns 20,185 shares of the company’s stock, valued at $808,207.40. The disclosure for this sale can be found here. Insiders sold a total of 274,477 shares of company stock valued at $10,869,598 over the last ninety days. 0.06% of the stock is currently owned by company insiders.

A number of brokerages have recently issued reports on PFE. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Tuesday, October 9th. Morningstar set a $46.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Tuesday, October 9th. Independent Research set a $48.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, October 4th. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Thursday, October 4th. Finally, Barclays reissued a “neutral” rating and set a $40.00 target price on shares of Pfizer in a research note on Wednesday, September 26th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and nine have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $42.80.

NYSE PFE opened at $44.57 on Thursday. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $45.81. The company has a market capitalization of $262.34 billion, a P/E ratio of 16.82, a PEG ratio of 2.23 and a beta of 0.96. The company has a quick ratio of 0.91, a current ratio of 1.16 and a debt-to-equity ratio of 0.41.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.07. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The firm had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. During the same period last year, the business posted $0.67 EPS. Pfizer’s quarterly revenue was up 4.4% on a year-over-year basis. On average, equities research analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Investors of record on Friday, November 9th will be paid a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 3.05%. The ex-dividend date is Thursday, November 8th. Pfizer’s payout ratio is currently 51.32%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Recommended Story: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.